In the present study, the relapse rate of patients with AQP4-Ab positive optic neuritis treated with satralizumab was as low as in previous reports, and the relapse rate was significantly reduced one year before and after the initiation of satralizumab, supporting the finding that satralizumab has a high relapse prevention effect. The gene discussed is AQP4; the disease is optic neuritis.